三抗市场再起波澜！艾伯维19.25亿美元引进一款产品

制药网07-14

【制药网行业动态】近日，艾伯维宣布与Ichnos Glenmark Innovation的全资子公司IGITherapeutics达成许可协议。根据协议，艾伯维将获得IGI的主要资产ISB2001在北美、欧洲、日本和大中华区的独家开发、生产和商业化权益。IGI则将获得7亿美元的预付款，同时还有资格获得高达12.25亿美元的开发、监管和商业化里程碑付款，外加基于净销售额的两位数分层特许权使用费，总...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2551974502?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-07-14 14:10","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2551974502","market":"us","top_or_hot":-1,"title":"三抗市场再起波澜！艾伯维19.25亿美元引进一款产品","media":"制药网","content":"<div>\n<p>【制药网 行业动态】近日，艾伯维宣布与Ichnos Glenmark Innovation的全资子公司IGITherapeutics达成许可协议。根据协议，艾伯维将获得IGI的主要资产ISB2001在北美、欧洲、日本和大中华区的独家开发、生产和商业化权益。IGI则将获得7亿美元的预付款，同时还有资格获得高达12.25亿美元的开发、监管和商业化里程碑付款，外加基于净销售额的两位数分层特许权使用费，总...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202507141413469541b2c2&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>三抗市场再起波澜！艾伯维19.25亿美元引进一款产品</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n三抗市场再起波澜！艾伯维19.25亿美元引进一款产品\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-07-14 14:10 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202507141413469541b2c2&s=b><strong>制药网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>【制药网 行业动态】近日，艾伯维宣布与Ichnos Glenmark Innovation的全资子公司IGITherapeutics达成许可协议。根据协议，艾伯维将获得IGI的主要资产ISB2001在北美、欧洲、日本和大中华区的独家开发、生产和商业化权益。IGI则将获得7亿美元的预付款，同时还有资格获得高达12.25亿美元的开发、监管和商业化里程碑付款，外加基于净销售额的两位数分层特许权使用费，总...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202507141413469541b2c2&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0965509283.SGD","symbol_name":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (SGDHDG) INC","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202507141413469541b2c2&s=b","article_id":"2551974502","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202507141413469541b2c2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2551974502","pubTimestamp":1752473456,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"IGI则将获得7亿美元的预付款，同时还有资格获得高达12.25亿美元的开发、监管和商业化里程碑付款，外加基于净销售额的两位数分层特许权使用费，总交易金额最高可达19.25亿美元，足以彰显双方对这款药物的高度信心。根据协议，艾伯维将支付给先声再明一定的预付款，以及最高10.55亿美元的选择性权益付款和里程碑付款，外加大中华区以外地区的销售分成。短短半年内，艾伯维在三抗领域连续出手，足以看出其对这一领域的重视和布局的决心。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU0965509283.SGD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (SGDHDG) INC","LU0234570918.USD":"高盛全球核心股票组合Acc Close","LU1244550221.USD":"FRANKLIN GLOBAL MULTI-ASSET  INCOME \"A\" (USDHEDGED) INC (M)","LU2112291526.USD":"BGF WORLD HEALTHSCIENCE \"A4\" (USD) INC","LU0320765646.SGD":"FTIF - Franklin Income A MDIS SGD-H1","LU1934455194.USD":"AB SICAV I LOW VOLATILITY TOTAL RETURN EQUITY PORT \"A\" (USD) ACC","LU0417517546.SGD":"Allianz US Equity Cl AT Acc SGD","LU0820561818.USD":"安联收益及增长平衡基金Cl AM DIS","LU1267930490.SGD":"TEMPLETON GLOBAL EQUITY INCOME \"AS\" (SGD) INC A","LU0708994859.HKD":"TEMPLETON GLOBAL \"A\" (HKD) ACC","ABBV":"艾伯维公司","LU0738911758.USD":"Blackrock Global Equity Income A6 USD","LU2133065610.SGD":"JPMorgan Investment Funds - Global Dividend A (mth) SGD","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","PK":"Park Hotels & Resorts Inc.","LU2347655156.SGD":"JPMorgan Investment Funds - Global Income A (icdiv) SGD-H","LU1244550494.USD":"FRANKLIN GLOBAL MULTI-ASSET INCOME \"A\" (USDHEDGED) ACC","LU0256863811.USD":"ALLIANZ US EQUITY \"A\" INC","ORR":"Militia Long/Short Equity ETF","IE00B7SZL793.SGD":"Legg Mason Royce - US Small Cap Opportunity A Acc SGD-H","LU1162221912.USD":"FRANKLIN INCOME \"A\" (USD) ACC","LU0882574055.USD":"富达全球健康医疗A ACC","BK4534":"瑞士信贷持仓","LU2129689514.USD":"FRANKLIN GLOBAL INCOME \"A\" (USD) INC","LU0203347892.USD":"SCHRODER ISF QEP GLOBAL ACTIVE VALLUE \"A\" (USD)  INC AV","LU2065731478.USD":"ALLSPRING (LUX) WORLDWIDE FUND - SMALL CAP INNOVA \"I\" (USD) ACC","LU1989771016.USD":"东方汇理环球老龄化投资基金 A2 Acc","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","PD":"PagerDuty, Inc.","LU1244550577.SGD":"FTIF - Franklin Global Multi-Asset Income A (Mdis) SGD-H1","TRAE":"Triton American Energy Corp.","IE00BVYPNW00.USD":"GUINNESS GLOBAL EQUITY INCOME \"C\" (USD) ACC","SG9999001440.SGD":"United Global Dividend Equity Fund A SGD Dist","LU0795875169.SGD":"JPMorgan Investment Funds - Global Income A (div) SGD-H","LU1989772840.SGD":"CPR Invest - Climate Action A2 Acc SGD-H","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","LU2237443549.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA SGD-H","LU1496350171.SGD":"FRANKLIN DIVERSIFIED BALANCED \"A\" (SGDHDG) ACC","SG9999015986.USD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (USD) ACC","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","IE00B19Z4B17.USD":"LEGG MASON ROYCE US SMALL CAP OPPORTUNITY \"A\" (USD) ACC","CRS":"卡朋特科技","LU2237443895.HKD":"abrdn SICAV I -  GLOBAL DYNAMIC DIVIDEND \"A\" (HKD) ACC","BK4588":"碎股","BK4550":"红杉资本持仓","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU1496350502.SGD":"FRANKLIN DIVERSIFIED DYNAMIC \"A\" (SGDHDG) ACC","LU0158827948.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"A\" (USD) INC","LU2237443978.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc SGD-H"},"translate_title":"The tertiary antibody market is making waves again! AbbVie introduces a product for $1.925 billion","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PK":1,"ABBV":0.9,"PD":1,"CRS":1,"TRAE":1,"ORR":1},"content_text":"【制药网 行业动态】近日，艾伯维宣布与Ichnos Glenmark Innovation的全资子公司IGITherapeutics达成许可协议。根据协议，艾伯维将获得IGI的主要资产ISB2001在北美、欧洲、日本和大中华区的独家开发、生产和商业化权益。IGI则将获得7亿美元的预付款，同时还有资格获得高达12.25亿美元的开发、监管和商业化里程碑付款，外加基于净销售额的两位数分层特许权使用费，总交易金额最高可达19.25亿美元，足以彰显双方对这款药物的高度信心。ISB2001是一种同类首创的CD3/BCMA/CD38三特异性T细胞衔接器。其独特之处在于能够同时靶向骨髓瘤细胞上的BCMA和CD38，以及T细胞上的CD3，这种多靶点协同作用的设计为治疗复发/难治性多发性骨髓瘤带来了新的希望。目前，该药物正处于I期临床研究阶段，专注于攻克复发/难治性多发性骨髓瘤这一棘手的疾病。这款药物的研发依托于IGI专有的BEAT®蛋白平台，该平台赋予了ISB2001出色的性能。平台设计了两种针对骨髓瘤相关抗原的不同结合剂，这使得药物即便在较低的靶标表达水平下也能增强亲和力，大大提升了对肿瘤细胞的识别和攻击能力。更重要的是，相比一代双特异性抗体，ISB2001在安全性上进行了优化，有望降低治疗过程中的不良反应，提高患者的耐受性。值得一提的是，它是目前全球范围内成功处于临床阶段的CD3/BCMA/CD38三抗，在同类药物中具有先发优势。ISB2001的临床潜力也得到了专业机构的认可。2023年7月，美国食品药品监督管理局(FDA)授予其孤儿药认定，这一认定不仅能为药物的研发和审批提供一系列便利，更体现了其在治疗罕见病领域的重要价值。2025年5月，FDA又授予其用于治疗复发/难治性骨髓瘤患者的快速通道指定，这将加速药物的开发和审评进程，让更多患者能早日受益。在今年的美国临床肿瘤学会(ASCO)大会上，ISB2001更是以快速口头报告的形式披露了I期试验的剂量递增结果(摘要编号#7514)，引发了业界的广泛关注。该研究针对接受过免疫调节药物、蛋白酶体抑制剂和抗CD38疗法治疗后复发或对现有疗法不耐受的多发性骨髓瘤患者，评估了ISB2001的安全性、耐受性、疗效、药代动力学(PK)和药效动力学(PD)。值得注意的是，研究对象允许接受过BCMA靶向治疗和/或T细胞靶向治疗，这意味着即便对于那些经过多线治疗、病情复杂的患者，该药物仍可能发挥作用。来自35名患者的数据显示，在接受过大量治疗的复发/难治性骨髓瘤患者群体中，当ISB2001的活性剂量≥50µg/kg时，持续总体缓解率(ORR)达到了79%，完全/严格完全缓解(CR/sCR)率更是高达30%，这样的疗效数据在同类治疗中表现亮眼，为患者带来了切实的希望。安全性方面，ISB2001表现出良好的耐受性。细胞因子释放综合征(CRS)事件可控，仅1例患者发生1级免疫效应细胞相关神经毒性综合征(ICANS)。在不良反应方面，有49%的患者发生了与治疗相关的≥3级血液学毒性；20%的患者发生了≥3级非血液学毒性的治疗相关不良事件(TRAE)。总体来看，药物的安全性在可控范围内，为后续的临床研究奠定了坚实基础。目前，ISB2001正在进入剂量拓展的第2阶段，旨在建立推荐的II期剂量(PR2D)和后期开发的最佳剂量表，为药物的进一步推广应用做好准备。从三抗市场的整体格局来看，与双抗竞争激烈的局面不同，三抗市场的竞争相对平和。其中，艾伯维在三抗领域的布局动作频频，除了与IGI的交易以外，2025年1月13日，先声药业旗下的抗肿瘤创新药公司先声再明曾宣布，已与艾伯维就其处于中国和美国临床I期研究阶段的GPRC5DxBCMAxCD3的TCE三抗管线SIM0500达成许可选择协议。根据协议，艾伯维将支付给先声再明一定的预付款，以及最高10.55亿美元的选择性权益付款和里程碑付款，外加大中华区以外地区的销售分成。短短半年内，艾伯维在三抗领域连续出手，足以看出其对这一领域的重视和布局的决心。目前，全球范围内共有7款同时靶向CD3和BCMA的三抗药物进入临床阶段，其中4款来自国内药企，包括信达生物的GPRC5D/BCMA/CD3三抗IBI3003、康源博创/天广实的MBS314、先声药业的SCR-8572以及齐鲁制药的QLS4131。国内药企在三抗领域的积极布局，不仅展现了中国生物医药产业的创新实力，也为全球三抗市场的发展注入了新的活力。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2551974502","isCrawlerRequest":true}